KPC Pharmaceuticals,Inc. (SHA:600422)
China flag China · Delayed Price · Currency is CNY
8.41
-0.08 (-0.94%)
Sep 10, 2026, 1:13 PM CST

KPC Pharmaceuticals,Inc. Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
4,7496,2727,9608,2667,7208,045
Other Revenue
118.29303.38441.93163.98562.24208.77
4,8676,5758,4018,4308,2828,254
Revenue Growth
-38.84%-21.74%-0.34%1.79%0.35%6.95%
Cost of Revenue
3,4144,0634,7714,5444,8554,865
Gross Profit
1,4532,5123,6313,8863,4273,389
Selling, General & Admin
1,6722,0872,5972,9832,8122,779
Research & Development
89.96102.55106.7694.269.65100.52
Other Operating Expenses
88.9150.2965.0468.06-57.2564.56
Operating Expenses
1,9342,2442,8143,1892,8642,980
Operating Income
-480.84268.1816.64696.42563.54409.19
Interest Expense
-40.42-50.59-26.36-21.61-40.73-33.59
Interest & Investment Income
69.3272.0127.7838.1412.05156.1
Currency Exchange Gain (Loss)
-5.21-0.231.922.083.08-3.48
Other Non Operating Income (Expenses)
-6.05-18.753.78-9.03-27.97-7.25
EBT Excluding Unusual Items
-463.2270.54823.75705.99509.97520.97
Impairment of Goodwill
-4.1-4.1----
Gain (Loss) on Sale of Investments
101.8108.916.921.0310.67-0.96
Gain (Loss) on Sale of Assets
1.850.671.011.0415.212.2
Asset Writedown
-4.94-9.17-2.04-30.12-57.73-0.29
Other Unusual Items
147.53106.69104.93108.45-0.84109.37
Pretax Income
-221.06473.56934.57786.38477.29631.29
Income Tax Expense
-20.554.5183.35143.791.83118.07
Earnings From Continuing Operations
-200.56419.05751.22642.67385.46513.21
Minority Interest in Earnings
-11.8-69.11-103.14-101.96-2.28-5.55
Net Income
-212.36349.94648.08540.71383.18507.67
Net Income to Common
-212.36349.94648.08540.71383.18507.67
Net Income Growth
--46.00%19.86%41.11%-24.52%11.12%
Shares Outstanding (Basic)
758761754762751758
Shares Outstanding (Diluted)
758761754762751758
Shares Change
0.02%0.95%-1.05%1.36%-0.84%-0.19%
EPS (Basic)
-0.280.460.860.710.510.67
EPS (Diluted)
-0.280.460.860.710.510.67
EPS Growth
--46.51%21.13%39.22%-23.88%11.33%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-554.1198.68728.63644.69152.1515.46
Free Cash Flow Per Share
-0.730.260.970.850.200.02
Dividend Per Share
0.1800.1800.3000.2000.1600.270
Dividend Growth
-40.00%-40.00%50.00%25.00%-40.74%17.39%
Gross Margin
29.85%38.21%43.22%46.10%41.38%41.06%
Operating Margin
-9.88%4.08%9.72%8.26%6.80%4.96%
Profit Margin
-4.36%5.32%7.71%6.41%4.63%6.15%
Free Cash Flow Margin
-11.39%3.02%8.67%7.65%1.84%0.19%
EBITDA
-329.45427.67991.12871.81744.03568.04
EBITDA Margin
-6.77%6.50%11.80%10.34%8.98%6.88%
D&A For EBITDA
151.38159.57174.48175.4180.49158.86
EBIT
-480.84268.1816.64696.42563.54409.19
EBIT Margin
-9.88%4.08%9.72%8.26%6.80%4.96%
Effective Tax Rate
-11.51%19.62%18.27%19.24%18.70%
Revenue as Reported
4,8676,5758,4018,4308,2828,254